Oncology

Redefining the treatment paradigm to eliminate cancer as a cause of death

Our approach

Even as research and development continues to break boundaries in how we understand and fight cancer, there are still more than eight million lives lost every year to the disease. At AstraZeneca, we are committed to advancing the science of oncology to deliver life-changing medicines to patients most in need. With a combination-focused pipeline that exploits the power of four scientific platforms to help address unmet clinical needs in a host of cancers, we are motivated by a dedication to the scientific discovery and collaboration that will one day help eliminate cancer as a cause of death.

Our focus on unmet needs

  • Immuno-oncology

    Using the body's immune system to help fight cancer

    Watch video
  • Tumour drivers and resistance

    Developing therapies that target specific mutations to attack cancer cells

    Watch video
  • DNA damage repair

    Targeting the DNA repair process to block tumour cells' ability to reproduce

    Watch video
  • Antibody-drug conjugates

    Arming antibodies with cancer-killing agents for specific tumour targeting

    Watch video

What we're working on

As part of our commitment to oncology, the following section provides further detail about key areas of focus.

Our pipeline

Our robust pipeline includes investigational therapies in varied stages of clinical development, from recently approved products to earlier-stage molecules in clinical trials. We aspire to transform the lives of cancer patients, working to eliminate cancer as a cause of death in the future.

Phase 3/Reg.* refers to assets that are in Phase 3 or that have been submitted for regulatory approval, and may include assets that are now launched in one or more major markets.

Oncology (as at 4 February 2016)

Phase 1

Phase 1

  • AZD0156 solid tumours
  • AZD2811 solid tumours
  • AZD5312 solid tumours
  • AZD6738 solid tumours
  • AZD8186 solid tumours
  • AZD8835 solid tumours
  • AZD9150 haematological malignancies
  • AZD9496 ER+ breast cancer
  • Iressa + durvalumab NSCLC
  • MEDI-551 + rituximab haematological malignancies
  • MEDI-565 solid tumours
  • MEDI0562 solid tumours
  • MEDI0639 solid tumours
  • MEDI0680 solid tumours
  • MEDI1873 solid tumours
  • MEDI3617 solid tumours
  • MEDI4276 solid tumours
  • MEDI6383 solid tumours
  • MEDI9197 solid tumours
  • MEDI9447 solid tumours
  • Tagrisso (AZD9291) + (durvalumab or selumetinib or savolitinib) TATTON advanced EGFRm NSCLC
  • durvalumab solid tumours
  • durvalumab + MEDI0680 solid tumours
  • durvalumab + MEDI6383 solid tumours
  • durvalumab + dabrafenib + trametinib melanoma
  • durvalumab + tremelimumab solid tumours

Phase 2

Phase 2

  • AZD1775 ovarian cancer
  • AZD2014 solid tumours
  • AZD3759 BLOOM Tagrisso (AZD9291) BLOOM brain metastases in advanced EGFRm NSCLC
  • AZD4547 solid tumours
  • AZD5069+durvalumab AZD9150+durvalumab SCCHN
  • AZD5363 breast cancer
  • MEDI-551 diffuse B-cell lymphoma
  • MEDI-573 metastatic breast cancer
  • durvalumab solid tumours
  • durvalumab + tremelimumab gastric cancer
  • savolitinib/ volitinib papillary renal cell carcinoma
  • selumetinib 2nd-line KRAS wt NSCLC

Phase 3/Reg.*

Phase 3/Reg.*

  • Tagrisso (AZD9291) AURA, AURA 2 ≥2nd-line advanced EGFRm T790M NSCLC
  • acalabrutinib B-cell blood cancers
  • cediranib ICON 6 PSR ovarian cancer
  • durvalumab PACIFIC stage III NSCLC
  • durvalumab HAWK 2nd-line SCCHN (PD-L1 positive)
  • durvalumab + tremelimumab ALPS metastatic pancreatic ductal carcinoma
  • durvalumab + tremelimumab ARCTIC 3rd-line NSCLC
  • durvalumab + tremelimumab CONDOR 2nd-line SCCHN (PD-L1 negative)
  • durvalumab + tremelimumab DANUBE 1st-line bladder
  • durvalumab + tremelimumab EAGLE 2nd-line SCCHN
  • durvalumab + tremelimumab KESTREL 1st-line SCCHN
  • durvalumab + tremelimumab MYSTIC 1st-line NSCLC
  • durvalumab + tremelimumab NEPTUNE 1st-line NSCLC
  • moxetumomab pasudotox PLAIT hairy cell leukaemia
  • selumetinib ASTRA differentiated thyroid cancer
  • selumetinib SELECT-1 2nd-line KRASm NSCLC
  • tremelimumab DETERMINE mesothelioma

LCM Projects

LCM Projects

  • Faslodex FALCON 1st-line hormone receptor +ve advanced breast cancer
  • Lynparza (olaparib) prostate cancer
  • Lynparza (olaparib) GOLD 2nd-line gastric cancer
  • Lynparza (olaparib) OlympiA gBRCA adjuvant breast cancer
  • Lynparza (olaparib) OlympiAD gBRCA metastatic breast cancer
  • Lynparza (olaparib) POLO pancreatic cancer
  • Lynparza (olaparib) SOLO-1 1st-line BRCAm ovarian cancer
  • Lynparza (olaparib) SOLO-2 2nd-line or greater BRCAm PSR ovarian cancer, maintenance monotherapy
  • Lynparza (olaparib) SOLO-3 gBRCA PSR ovarian cancer
  • Tagrisso (AZD9291) ADAURA adjuvant EGFRm NSCLC
  • Tagrisso (AZD9291) AURA 3 ≥2nd-line advanced EGFRm T790M NSCLC
  • Tagrisso (AZD9291) FLAURA 1st-line advanced EGFRm NSCLC
  • Tagrisso (AZD9291)+durvalumab CAURAL ≥2nd-line advanced EGFRm T790M NSCLC

Our medicines

Please note that the products mentioned may not be available in all countries. Additionally, currently approved indications (uses) and presentations may differ between countries. Country specific information is available from your local AstraZeneca company.

  • Arimidex anastrozole
  • Casodex, Cosudex bicalutamide
  • Faslodex fulvestrant
  • Iressa gefitinib
  • Lynparza olaparib
  • Nolvadex, Istubal, Valodex tamoxifen citrate
  • Zoladex goserelin acetate implant

Partnering to address unmet needs

To eradicate cancer as a cause of death, we understand that we cannot work alone. Improving patient outcomes requires a collaborative approach to research and development.

Commitment to science

Our commitment to science is reflected in our track record of publications. Here are a few recent examples of high impact and high quality publications co-authored by AstraZeneca and/or MedImmune scientists.

Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations.

PUBLISHED
May 2015

TITLE
Low-frequency coding variants at 6p21.33 and 20q11.21 are associated with lung cancer risk in Chinese populations.

AstraZeneca/MedImmune AUTHOR
Brandon Higgs (Oncology, MedImmune)

Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress

PUBLISHED
January 2015

TITLE
Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress.

Resources